PharmaCyte Biotech Inc. (PMCB)
| Bid | 1.46 |
| Market Cap | 11.08M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | 20.69M |
| EPS (ttm) | 0.88 |
| PE Ratio (ttm) | 1.81 |
| Forward PE | -4.24 |
| Analyst | n/a |
| Ask | 1.73 |
| Volume | 4,435 |
| Avg. Volume (20D) | 18,187 |
| Open | 1.67 |
| Previous Close | 1.64 |
| Day's Range | 1.50 - 1.67 |
| 52-Week Range | 1.39 - 2.58 |
| Beta | -0.25 |
About PMCB
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is deve...
2 years ago · businesswire.com
PharmaCyte Biotech to Implement Second $10-Million Share Repurchase PlanLAS VEGAS--( BUSINESS WIRE )--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), a biotechnology company focused on evaluating its signature live-cell encapsulation technology, Ce...
2 years ago · businesswire.com
PharmaCyte Biotech Rebukes Iroquois' Commencement of Consent SolicitationLAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature li...
2 years ago · businesswire.com
PharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent SolicitationLAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature li...